Morningstar

Dyne Therapeutics Inc Ordinary Shares DYN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$32.58 −0.97 (2.89%)
View Full Chart
As of Delayed Price Post-Trading: $36.59 +4.01

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
DYN is trading at a 158% premium.
Price
$33.71
Fair Value
$56.86
Uncertainty
Extreme
1-Star Price
$1,122.53
5-Star Price
$7.82
Economic Moat
Gwcc
Capital Allocation
—

News

View All

Trading Information

Previous Close Price
$33.55
Day Range
$32.39–34.00
52-Week Range
$6.40–47.45
Bid/Ask
$32.05 / $32.56
Market Cap
$3.27 Bil
Volume/Avg
1.2 Mil / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
152
Website
https://www.dyne-tx.com

Comparables

Valuation

View More
Metric
DYN
CTNM
UTHR
Price/Earnings (Normalized)
 ——14.90
Price/Book Value
 4.332.092.73
Price/Sales
 ——6.58
Price/Cash Flow
 ——14.11
Price/Earnings
DYN
CTNM
UTHR

Financial Strength

Metric
DYN
CTNM
UTHR
Quick Ratio
 26.1858.483.92
Current Ratio
 26.6358.924.35
Interest Coverage
 ——22.67
Quick Ratio
DYN
CTNM
UTHR

Profitability

Metric
DYN
CTNM
UTHR
Return on Assets (Normalized)
 −55.93%−18.15%16.95%
Return on Equity (Normalized)
 −64.68%−871.68%20.53%
Return on Invested Capital (Normalized)
 −63.67%−892.99%16.62%
Return on Assets
DYN
CTNM
UTHR

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
SywkybyjHsr$516.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
CtcmzzqnWdzxwb$117.1 Bil
 Regeneron Pharmaceuticals Inc
REGN
RfzzwdqdNzxrhhd$111.8 Bil
 Alnylam Pharmaceuticals Inc
ALNY
PywpzdtsQvqwh$34.6 Bil
 argenx SE ADR
ARGX
VssvfctxtMlvy$33.0 Bil
 BioNTech SE ADR
BNTX
RzwkkqytKxvr$28.5 Bil
 Moderna Inc
MRNA
GjszrtrsBzyn$23.5 Bil
 United Therapeutics Corp
UTHR
HblhpwrnNngvm$15.6 Bil
 Biomarin Pharmaceutical Inc
BMRN
RvmfwpbsxKhshzq$13.0 Bil
 Incyte Corp
INCY
RsmhsrxgbCyjlqp$12.9 Bil

Sponsor Center